Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 5,750,000 shares, an increase of 34.3% from the May 31st total of 4,280,000 shares. Based on an average daily volume of 834,000 shares, the short-interest ratio is presently 6.9 days.
Applied Therapeutics Stock Performance
Shares of Applied Therapeutics stock opened at $4.67 on Monday. The business’s 50 day moving average price is $4.49 and its 200 day moving average price is $4.47. The company has a market cap of $533.63 million, a price-to-earnings ratio of -2.54 and a beta of 1.88. Applied Therapeutics has a one year low of $1.18 and a one year high of $9.39.
Applied Therapeutics (NASDAQ:APLT – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $10.00 million. On average, analysts predict that Applied Therapeutics will post -0.59 EPS for the current fiscal year.
Insider Activity at Applied Therapeutics
Hedge Funds Weigh In On Applied Therapeutics
A number of institutional investors have recently bought and sold shares of APLT. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Applied Therapeutics during the 3rd quarter worth approximately $1,139,000. Armistice Capital LLC acquired a new stake in Applied Therapeutics during the third quarter worth $8,466,000. Rock Springs Capital Management LP raised its position in Applied Therapeutics by 3.6% in the third quarter. Rock Springs Capital Management LP now owns 808,809 shares of the company’s stock valued at $2,014,000 after purchasing an additional 28,018 shares during the period. Worth Venture Partners LLC acquired a new position in shares of Applied Therapeutics in the 3rd quarter valued at $483,000. Finally, Citigroup Inc. purchased a new position in shares of Applied Therapeutics during the 3rd quarter worth $164,000. 98.31% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $12.00 price objective on shares of Applied Therapeutics in a research note on Thursday, April 11th. UBS Group increased their target price on shares of Applied Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $11.00.
Check Out Our Latest Stock Report on Applied Therapeutics
Applied Therapeutics Company Profile
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Read More
- Five stocks we like better than Applied Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What is MarketRank™? How to Use it
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.